Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Simple Summary Numerous mechanisms of glioblastoma (GBM) radioresistance have been
identified but have not yet resulted in development of effective radiosensitizer that can …

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a …

Several commonly prescribed antiepileptic drugs (AEDs)—including phenobarbital,
phenytoin, and carbamazepine—stimulate the synthesis of a broad range of …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Abstract Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal
improvements in survival seen following currently available salvage therapy. This study was …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Glioma has been considered resistant to chemotherapy and radiation. Recently,
concomitant and adjuvant chemoradiotherapy with temozolomide has become the standard …

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and one
of the most aggressive cancers in man. Despite technological advances in surgical …

Purpose This open-label, prospective, single-arm, phase II study combined erlotinib with
radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and …